RxDoctor Payments DataLook up a doctor →

Thomas Pollard, DO

Pulmonary Disease · Peoria, AZNPI 1710069885

Payments from drug & device makers

$88,074in general payments, 2019–2025

Across 1,108 payments — averaging $79.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$26K
  • GSK$20K
  • United Therapeutics Corporation$13K
  • Viatris Specialty LLC$12K
  • AstraZeneca$4K
  • Sanofi$3K
  • plus $10K from 44 others

What the payments were for

  • Consulting fees$1,3462%
  • Speaking & faculty fees$57,55265%
  • Travel & lodging$4,9316%
  • Food & beverage$23,85427%
  • Education$3920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,074 in reported general payments places this provider in the 85th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$262,288
Medicare patients
575
Services billed
2,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter562$469,539
Stiolto RespimatTiotropium Br/Olodaterol Hcl176$111,631
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$79,702
Spiriva RespimatTiotropium Bromide110$69,340
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$29,455
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$19,899
SymbicortBudesonide/Formoterol Fumarate52$15,725
Albuterol Sulfate HfaAlbuterol Sulfate489$13,401
Spiriva HandihalerTiotropium Bromide15$12,263
Wixela InhubFluticasone Propion/Salmeterol60$10,632
Incruse ElliptaUmeclidinium Bromide18$6,194
Vancomycin Hcl30$6,041
AirsupraAlbuterol Sulfate/Budesonide13$5,987
Roflumilast49$4,660
Advair DiskusFluticasone Propion/Salmeterol17$4,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$19,756$505,189618 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$26,455$180,972286 claims
AstraZenecaBreztri Aerosphere, Symbicort, Airsupra$4,026$101,414162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →